ArticleCurrent opinion in toxicology2026
NGRA in Cosmetic Safety: Moving From the Frameworks and Case Studies to Wide Adoption.
Article in Current opinion in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The cosmetic safety evaluation has undergone a paradigm shift driven by animal testing bans now implemented across countries representing one-third of the global population and nearly half of worldwide cosmetics sales. The legislative mandates have accelerated the development and adoption of Next Generation Risk Assessment (NGRA), an innovative framework that proposes making of context-specific safety decisions using exposure-driven, mechanism-based approaches based on non-animal test methods. Significant progress has been achieved in replacing animal tests for specific endpoints including skin sensitization, irritation, and phototoxicity through validated New Approach Methodologies (NAMs). However, major gaps remain for one-for-one replacement of systemic toxicity, reproductive and developmental toxicity, and carcinogenicity animal tests. Recent advances demonstrate that NGRA can successfully address many of these complex endpoints through integrated approaches combining physiologically-based kinetic (PBK) modeling, high-throughput transcriptomics and
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.